Stifel Downgrades Vor Biopharma, Inc. (VOR) to Hold

Stifel analyst Stephen Willey downgraded Vor Biopharma, Inc. (NASDAQ: VOR) from Buy to Hold with a price target of $0.30 (from $5.00).

The analyst comments: "Our conversation with management suggested this decision reflects a combination of both clinical data evaluated to date and the challenging financing environment currently characterizing the biotech sector. Management intimated the preliminary VCAR33 dose-escalation data anticipated in 1H25 (presumably at EHA in June) will still be presented by trial investigators as originally planned. However, management commentary also seemed to suggest there was likely something observed within this data set which would’ve challenged/complicated the ability to pursue the 2H25 initiation of a trem-cel/VCAR33 Treatment System trial (as recent guidance suggested). As a result, management is now currently considering all possible strategic alternatives and has implemented a ~95% workforce reduction that will generate $11M in severance/restructuring expenses. Our updated target price of $0.30/share (previously $5/share) now reflects our fully-diluted share (excluding out-of-the-money warrants) estimate of 2Q25-ending net cash/equivalents ($43M). Recall, VOR ended FY24 with ~$92M in cash/equivalents and had previously provided cash runway guidance into 1Q26."

For an analyst ratings summary and ratings history on Vor Biopharma, Inc. click here. For more ratings news on Vor Biopharma, Inc. click here.

Shares of Vor Biopharma, Inc. closed at $0.54 yesterday.

You May Also Be Interested In

• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
• FGI Industries (FGI) PT Raised to $13 at Benchmark as Full Year Guide Reiterated
• QXO (QXO) Reiterated at Buy by Benchmark Amid Muted Industry Demand